Lonza and ValenzaBio Enter Manufacturing Agreement to Rapidly Advance VB421, an anti-IGF-1R Antibody for Autoimmune Diseases
by
Excerpt Lonza and ValenzaBio have entered an agreement for the accelerated manufacturing of VB421, an anti-insulin-like growth factor 1 receptor (anti-IGF-1R) under evaluation for the treatment of thyroid eye disease (TED) and other autoimmune and fibrotic diseases. Lonza will leverage its global network and local operation capabilities, as well as its new manufacturing facility in […]
Biosimilar producer looking to get first to market advantage in China and Europe
by
Excerpt Bio-Thera Solutions, a biopharmaceutical company based in Guangzhou, China, has initiated the first Phase 3 study of a golimumab biosimilar in China and Eastern Europe, which is expected to enrol 598 subjects and achieve completion by October 2023. As the first golimumab biosimilar to gain approval in multiple countries, BAT2506 gives Bio-Thera Solutions early […]
